7492-31-1

Usage

Uses

Used in Pharmaceutical Industry:
Isometheptene mucate is used as an active pharmaceutical ingredient for the treatment of migraines and headaches. Its application is primarily due to its vasoconstricting activity, which helps alleviate the symptoms associated with these conditions.
Used in Migraine Relief Formulations:
Isometheptene mucate is used as a key component in migraine relief formulations, where it serves to provide relief from the pain and discomfort caused by migraines. Its effectiveness is attributed to its ability to constrict blood vessels and reduce inflammation in the affected areas.
Used in Pain Management:
Isometheptene mucate is utilized as a pain management agent, particularly for conditions involving inflammation and vascular congestion. Its sympathomimetic properties allow it to effectively reduce pain and promote a sense of relief in individuals suffering from various types of pain.

InChI:InChI=1/2C9H19N.C6H10O8/c2*1-8(2)6-5-7-9(3)10-4;7-1(3(9)5(11)12)2(8)4(10)6(13)14/h2*6,9-10H,5,7H2,1-4H3;1-4,7-10H,(H,11,12)(H,13,14)/t;;1-,2+,3+,4-

Upstream product

• 526-99-8 meso-galactaric acid 
• 1620401-54-8 (S)-6-methylamino-2-methylheptene 
• 58917-27-4 (R)-sulcatol 
• 1620401-56-0 (R)-6-methylamino-2-methylheptene 
• 35189-96-9 3-methyl-2-butenylmagnesium chloride 
• 58917-26-3 (S)-sulcatol 
• 1620401-61-7 (S)-methanesulfonic acid 1,5-dimethyl-hex-4-enyl ester 
• 110-93-0 6-Methyl-hept-5-en-2-on 

Relevant academic research and scientific papers

IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS

This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in some embodiments, modulators (e.g., agonists), for the imidazoline receptor type 1.

NOVEL (R)-ISOMETHEPTENE COMPOSITIONS AND USES

The invention relates to the preparation and characterization of novel salts of (R)-isometheptene and crystalline forms thereof; moreover, the invention describes the use of the novel salts alone or in combination with other therapeutic salts for treatmen

ISOMETHEPTENE ISOMER

The invention relates to a purified Isometheptene compound comprising the structure according to Formula (I), or a hydrochloride, or a pharmaceutically acceptable addition salt thereof. In particular, the disclosure relates to the synthesis, purification and characterization of an Isometheptene isomer mucate crystal 2, wherein the Isometheptene isomer 2 is stereochemically characterized as (R)-enantiomer, respectively. The Isometheptene (R)-enantiomer activity indicates a selective centrally acting selective ligand for Imidazoline subtype 1 (I1) receptor sites; and more specifically, the disclosure provides an antihypertensive composition for treatment of migraine and other neurovascular or neurogenic pain from abdominal distress. (R)-Isometheptene enantiomer or isomer 2 may be an anti-hypertensive agent with lower side effects than the racemate form. Therefore (R)-Isometheptene is believed to be effective against episodic tension-type headaches (ETTH). The (R)-Isometheptene enantiomer or isomer 2 is believed to effectively lower blood pressure, used alone or together with other headache ameliorating drugs. Methods of synthesis and treatment are described. Regarding (R)-Isometheptene crystals data of X-ray crystallography are presented.